GSK plc position in VIR
VIR BIOTECHNOLOGY INC · Health Care
GSK plc reported holding 8,550,954 shares of VIR (VIR BIOTECHNOLOGY INC) in its Q3 2026 13F filing — a position valued at US$95.6M, representing 19.23% of its reported portfolio and ranking #2 among its reported holdings. GSK plc has disclosed VIR holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-06 · Source: SEC EDGAR Form 13F-HR
How GSK plc's VIR position evolved
GSK plc first disclosed a stake in VIR in Q4 2025 at 8,550,954 shares (US$51.6M). The position peaked in Q3 2026 at 8,550,954 shares, worth US$95.6M. Across 4 filings, GSK plc held the position steady without any share-count change. The most recent filing (Q3 2026) shows 8,550,954 shares valued at US$95.6M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 8.55M | $51.56M | New |
| Q1 2026 | 8.55M | $76.62M | Hold |
| Q2 2026 | 8.55M | $87.13M | Hold |
| Q3 2026 | 8.55M | $95.60M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VIR and 13F data
VIR (VIR BIOTECHNOLOGY INC) is a Health Care company. 49 other funds we track also report a position in VIR — the largest reported positions include ARCH Venture Management, LLC (US$129.4M), SB INVESTMENT ADVISERS (UK) LTD (US$111.6M), ADAR1 Capital Management, LLC (US$25.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VIR
- ARCH Venture Management, LLC 12.69M sh · $129.35M · Q2 2026
- SB INVESTMENT ADVISERS (UK) LTD 10.95M sh · $111.56M · Q2 2026
- ADAR1 Capital Management, LLC 2.46M sh · $25.03M · Q2 2026
- Boxer Capital Management, LLC 1.87M sh · $19.01M · Q2 2026
- GordonMD Global Investments LP 1.35M sh · $13.79M · Q2 2026
- Sio Capital Management, LLC 1.08M sh · $10.96M · Q2 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 853.68K sh · $8.70M · Q2 2026
- Saturn V Capital Management LP 770.64K sh · $7.85M · Q2 2026
- Jones Hill Capital LP 659.21K sh · $6.72M · Q2 2026
- Avidity Partners Management LP 519.30K sh · $5.29M · Q2 2026
- Alta Partners Management Company, L.P. 509.92K sh · $5.20M · Q2 2026
FAQ
How long has GSK plc held VIR?
GSK plc has disclosed VIR holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is GSK plc's current position in VIR?
As of Q3 2026, GSK plc holds 8.55M shares of VIR (VIR BIOTECHNOLOGY INC), valued at $95.60M, representing 19.23% of its reported portfolio and ranking #2.
Has GSK plc been buying or selling VIR?
In the latest 13F filing (Q3 2026), GSK plc held unchanged its position in VIR. The position peaked in Q3 2026 at 8.55M shares.
Which other funds hold VIR?
Other major institutional holders of VIR include ARCH Venture Management, LLC, SB INVESTMENT ADVISERS (UK) LTD, ADAR1 Capital Management, LLC, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.